

DR. ROBERT MEEK (Orcid ID : 0000-0002-3104-0780)

Article type : Original Contribution

## **Randomized placebo-controlled trial of droperidol and ondansetron for adult emergency department patients with nausea.**

Robert Meek<sup>1,2</sup>, MBBS, MClInEpi; Michaela J. Mee<sup>1,2</sup>, MBBS; Diana Egerton-Warburton<sup>1,2</sup>, MBBS, MPH; Andis Graudins<sup>1,2</sup>, MBBS, PhD; Alastair Meyer<sup>1,2</sup>, MBBS; Pourya Pouryahya<sup>1,2</sup>, MD; Gabriel Blecher<sup>1,2</sup>, MBBS; James Fahey<sup>2</sup>; Sallyanne Crow<sup>1</sup>, BN(Hons).

<sup>1</sup> Emergency Medicine Program, Monash Health, Melbourne, Victoria, Australia;

<sup>2</sup> Department of Medicine, Monash University, Melbourne, Victoria, Australia;

### **Corresponding Author:**

A/Prof Robert Meek

Emergency Department, Dandenong Hospital

David Street, Dandenong, Victoria, 3101. Australia.

Phone: +61 3 95548475; Fax: +61 3 95548453

Email: robertmeek66@hotmail.com

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/acem.13650

This article is protected by copyright. All rights reserved.

## **Running title:**

Droperidol and ondansetron versus placebo for ED nausea

## **Funding**

The authors received AUD\$10,000.00 from the Morson Taylor Research Grant, administered by the Australasian College for Emergency Medicine, and AUD\$25,000.00 from the Monash Health Emergency Research Fund. The large majority of these funds were required for the preparation of the study medications by the Monash Clinical Trials Pharmacy. The residual covered various local administrative costs and payment for specialist statistical services.

## **Conflicts of Interest**

All authors (RM, MJM, DEW, AG, AM, PP, GB, JF, SC) report no conflicts of interest.

## **Author Contributions**

RM, DEW and MJM conceived the study; all co-authors had significant input in to study design. Study conduct was supervised at the Dandenong Hospital site by RM, AG and SC; at Monash Medical Centre by MJM, DEW, GB and JF; at Casey Hospital by PP and AM. Study education at all sites was conducted by JF, with assistance at particular sites from RM, SC, MM and PP. Data collection and data entry was managed by RM (recruited patients) and SC (non-recruited patients). Statistical analyses were performed by RM, with advice from biostatisticians in the Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. All authors contributed substantially to the manuscript; RM takes responsibility for the paper as a whole.

## Abstract

**Objective:** To separately compare effectiveness of intravenous (IV) droperidol 1.25 mg and ondansetron 8 mg IV with 0.9% saline placebo for adult emergency department (ED) patients with nausea. A novel primary outcome measure, expected to aid clinical interpretation of reported results, was employed.

**Methods:** A randomised controlled trial was conducted at the three EDs of Monash Health, Melbourne, Australia. Design was to demonstrate superiority of the active drugs over placebo. The primary outcome measure of symptom improvement was defined as a visual analog scale (VAS) rating change of  $\geq -8$  mm from baseline at 30-minutes post-treatment. Mean VAS changes per group, and percentages experiencing the desired treatment effect were also compared. The study was concluded after recruitment of 215 of the planned 378 patients, as interim analysis confirmed that continuation could not result in a finding of superiority.

**Results:** Of 215 patients, 73 (34%), 71 (33%) and 71 (33%) received droperidol, ondansetron and placebo. Symptom improvement occurred in 75% (95% CI: 64 - 85), 80% (95% CI: 69 - 89) and 76% (95% CI: 64 - 85), respectively. Mean VAS changes were -29 mm (95% CI: -36 to -23), -34 mm (95% CI: -41 to -28), and -24 mm (95% CI: -29 to -19), respectively. Desired treatment effect was experienced by 77% (95% CI: 65 - 86), 73% (95% CI: 61 - 83) and 59% (95% CI: 47 - 71), respectively.

**Conclusion:** For adult ED patients with nausea, superiority was not demonstrated for droperidol or ondansetron over placebo.

# **A randomized placebo-controlled trial of droperidol and ondansetron for treatment of adult emergency department patients with nausea.**

## **Introduction**

Emergency department (ED) patients commonly suffer nausea and vomiting as part of their presenting symptom complex.<sup>1</sup> Effective treatment is desirable to alleviate patient distress and to reduce the potential for complications. Surveys report that ED patients with nausea expect to receive antiemetic drugs, and that ED doctors are willing to prescribe them.<sup>2,3</sup> ED-based trials, however, have failed to demonstrate superiority for commonly used antiemetic drugs over placebo.<sup>4-7</sup> Doubts have been expressed about these seemingly counter-intuitive findings.<sup>8,9</sup>

Possible limitations of the currently used outcome measures for the detection of real differences and the difficulty of interpreting the main study results have been highlighted.<sup>10,11</sup>

From 2000 to the present time, ED-based antiemetic trials have all used the standard 100 mm visual analog scale (VAS).<sup>4-6,12-15</sup> Patients rate severity at baseline and after a defined post-treatment period; the change is measured in mm. Use of the VAS to monitor nausea severity has a number of advantages. It reliably discriminates between severity subgroups,<sup>16,17</sup> is sensitive for the detection of change and is easy for patients to use and understand.<sup>18</sup> Difference in mean VAS change between treatment groups has been the primary outcome measure for all three ED-based placebo-controlled trials conducted to date.<sup>4-6</sup> Findings of superiority or equivalence have been based on the statistical significance of the between-group differences, but the clinical interpretation of these results is not straightforward.<sup>10</sup> The 'minimum clinically significant difference' (MCSD) for nausea on the VAS, defined as the mean VAS change reported by people who describe their symptoms as being 'a little less', was intended to address this difficulty.<sup>16,17</sup> While the MCSD varies a little with baseline

This article is protected by copyright. All rights reserved.

severity, it is generally accepted as being between -15 and -20 mm.<sup>16,17</sup> Its usefulness as an aid in antiemetic research, however, has proved to be limited. The seven ED-based antiemetic studies published from 2000 to 2014, reported mean VAS changes of between -22 mm and -41 mm for sixteen of the nineteen different treatment groups.<sup>4-6,12-15</sup> As these changes are greater than the MCSD, it can only be inferred that most patients in all groups were improved to some degree. Even if a between-group difference is statistically significant, the clinical significance is difficult to determine when the mean VAS change for both groups is in excess of the MCSD.<sup>10</sup>

To reconsider the prerequisite for a primary outcome measure, it should provide the best evidence with regard to the primary objective. The primary objective of antiemetic treatment for ED patients with nausea is clinically significant symptom improvement. Mean group VAS change does not provide direct evidence for this objective.<sup>10,11</sup> Recent research has demonstrated that ED patients with symptom improvement ('a little less' or 'a lot less') reliably report VAS reductions in excess of -8 mm.<sup>11,19</sup> This is not surprising, since when symptoms remain 'the same', multiple studies have reported the upper 95% confidence limits of the reported VAS change for this group to be between -5 mm and -9 mm.<sup>11,16,17</sup> It follows logically that if symptoms are no longer 'the same', they are almost certain to be improved. One study has also found that percentage VAS change from baseline also accurately predicts symptom improvement, with a best cut-off level of -20%.<sup>19</sup> From an analysis point of view, compared with treating VAS change as a continuous variable, its reduction to a binary outcome must lessen its sensitivity for detection of between-group differences.<sup>20</sup> This may seem undesirable, but the advantage in this setting is that it will allow the primary objective of symptom improvement to be directly compared between groups.<sup>10,11</sup> In conjunction with more standardly used outcome measures, this should aid the clinical interpretability of results. In turn, this may help clarify the issue of antiemetic drug effectiveness for ED patients,<sup>10</sup> but the usefulness of VAS change cut-off levels is yet to be demonstrated in a prospective antiemetic trial.

The aim of this study was to separately compare droperidol and ondansetron to placebo for the treatment of adult ED patients with nausea. The primary outcome was symptom improvement, which was defined using a measured VAS change cut-off level of -8 mm. Mean measured VAS change, mean percentage VAS change, a percentage VAS change cut-off level of -20%, and patients' experiencing of the desired treatment effect were included as secondary outcomes.

## **Methods**

### **Study design, setting and period**

A triple blind, randomized, controlled trial was designed to demonstrate the superiority of two antiemetic drugs, droperidol and ondansetron, over placebo. The study was conducted at the three EDs of Monash Health, Melbourne, Victoria, Australia. These are: Monash Medical Centre (tertiary referral hospital, ED annual census 79,000 patients), Dandenong Hospital (urban district hospital, ED annual census 72,000 patients), Casey Hospital (urban district hospital, ED annual census 67,000 patients). A convenience sample of eligible patients was recruited from 1 April 2017 to 10 November 2017. The trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617000224325). Study conduct was approved by the Monash Health Human Research Ethics Committee (HREC).

## Eligibility criteria

### Inclusion

Patients aged 18 years or more, with nausea severity at recruitment of 4 or more from any underlying cause. The severity screening used an 11-point verbal rating scale, with 0 being described as no nausea and 10 as the worst nausea imaginable.

### Exclusion

1) Allergy to ondansetron or droperidol. 2) Prior use (previous 4 hours) of an antiemetic drug (including ondansetron, droperidol, metoclopramide, promethazine, chlorpromazine, prochlorperazine and any steroid medication). This was done to prevent potential confounding from any of: residual ongoing effects of the previously administered drug; possible receipt of varying doses of a study drug; uncertain effect on outcome of receipt of multiple antiemetics from different drug groups. 3) Too unwell to participate for any reason (e.g. cardiovascular instability or altered mental state). This was subjectively at the discretion of the attending physician and was not further defined. 4) Contraindication to a normal saline infusion (e.g. fluid-restricted patients). 5) Parkinson's disease or restless leg syndrome. 6) Current use of a dopamine antagonist medication (including amisulpride, chlorpromazine, clopenthixol or flupenthixol, domperidone, haloperidol, paliperidone, quetiapine, risperidone, thioridazine). 7) Cognitive impairment or language barrier compromising study understanding. 8) Pregnant or breast feeding women. 9) Chemotherapy or radiotherapy induced nausea.

## Objectives and measures

**Primary objective:** Between-group comparisons of the number (percentage) of patients with a measured VAS change of  $\geq -8$  mm.

**VAS-related secondary objectives:** Between-group comparisons of mean measured VAS change; between-group comparisons of mean percentage VAS change; between-group comparisons of the number (percentage) of patients with a percentage VAS change of  $\geq -20\%$ .

**VAS-related outcome measures:** Nausea severity was rated at baseline (t0) and 30-minutes (t30) post-treatment on a VAS. The VAS was labelled as 'no nausea' at the left and 'worst nausea imaginable' at the right. Measures in mm were taken from the left end. Measured change was calculated as  $t30 - t0$ , as per previous literature. Percentage change was calculated as  $(t30 - t0)/t0$ . Measured and percentage VAS change cut-off levels of -8 mm and -20% were used to categorize patients as 'improved' or 'non-improved'. At the time of trial registration, use of only a measured VAS change cut-off of -5 mm was planned. This was based on the one relevant report available at the time.<sup>11</sup> The measured cut-off was altered to -8 mm and the -20% cut-off included due to the findings of a currently unpublished study.<sup>19</sup> This analysis pooled data from three nausea measurement studies which linked VAS and described change in a similar way.<sup>3,11,17</sup> ROC curve analyses found that both measured and percentage VAS change had equally high accuracy for detection of symptom improvement, with best cut-points of -8 mm and -20%.



### **Other secondary objectives and measures:**

1) Between-group comparisons of number (percentage) of patients experiencing the desired treatment effect. This was elicited from direct questioning: 'The drug I received had the desired effect for me: Yes or No'. 2) Number (percentage) of patients requesting additional antiemetic drugs. 3) Adverse events are reported for each group. The most frequently expected events of agitation/sedation (droperidol), dizziness (droperidol) and headache (ondansetron) were specifically assessed. The presence and degree of agitation or sedation was rated on the Richmond Agitation-Sedation Scale (RASS) at the time of the 30-minute nausea severity rating by the attending physician (+4 = Combative, +3 = Very agitated, +2 = Agitated, +1 = Restless, 0 = Alert and calm, -1 = Drowsy, -2 = Light sedation, -3 = Moderate sedation, -4 = Deep sedation, -5 = Unroutable). Presence/severity of headache and dizziness were rated on an adjectival scale as none, mild, moderate or severe. Any other adverse events of any type were to be noted as free text.

### **Randomization, blinding and study drug preparation**

A simple (non-block, non-stratified) randomization list was generated in the Monash Clinical Trials Pharmacy, where the study drugs were then prepared. Study drugs appeared identical as four mL of clear fluid in a five mL syringe. Each syringe was labeled with a unique study identification number, the HREC study reference number and an expiry date. These were kept refrigerated and had a shelf-life of seven days. Prepared study drugs were delivered to each ED as required. While randomization was non-block, initial deliveries to the Dandenong Hospital, Monash Medical Centre and Casey Hospital sites commenced respectively at number one, number 200 and number 300 on the randomization list. Subsequent deliveries to each site followed in numerical order from those starting numbers.

## Study drugs

a) **Droperidol** (Droleptan®, Phebra Pty Ltd, Sydney, NSW, Australia). One half mL from the 2.5 mg/mL ampoule was diluted with 3.5 mL of 0.9% saline to make a total of 1.25 mg in 4 mL.

b) **Ondansetron** (Ondansetron MYX, Mayne Pharma International Pty Ltd, Salisbury South, SA, Australia). Two of the 4 mg/mL ampoules remained undiluted to make a total of 8 mg in 4 mL.

c) **Placebo**: The syringe contained 4 mL of 0.9% sodium chloride.

**Study drug choice**: Droperidol 1.25 mg IV is the only antiemetic drug to have shown a statistically significant greater reduction in mean VAS rating in comparison with placebo.<sup>4</sup> Ondansetron is the most commonly used antiemetic in the ED setting;<sup>2</sup> the 8 mg IV dose was chosen as studies have reported 4 mg IV ondansetron to be equivalent with placebo.<sup>5,6</sup>

## Recruitment and study procedure

Study education took place prior to, and throughout the study period. Sixteen final year medical students volunteered to assist with recruitment and underwent training with regard to conduct of the study. They were present at a range of times between 08:00 and 24:00, on a variety of days at any of the three study sites. When present, the student assistants monitored the electronic ED tracking system in order to identify patients with nausea. On these occasions the student would check eligibility by completing an enrollment form which detailed the inclusion and exclusion criteria. If eligible, the student obtained consent, and engaged with the clinical staff for the required study drug and IV fluid prescriptions. Attending emergency physicians were also asked to consider recruitment of any patient for whom they intended prescribing an IV antiemetic drug for nausea from any underlying cause. If a student assistant was present, they were notified and assisted with

the study requirements. If no student was present, the attending physician was asked to complete the enrollment form and obtain informed consent. This enabled patients to be recruited at any time of any day, regardless of whether a student assistant was present or not. It was not feasible to have student assistants present at all sites on every shift of every day. Following enrollment, an IV infusion of 0.9% saline at a rate of 1000 mL over 4 hours was commenced and the study drug was obtained from the ED Medication Room refrigerator. After recording the baseline VAS rating, the study drug was administered as a hand-delivered, two-minute IV infusion. At 30-minutes post-treatment, the second VAS rating was taken. At this time, the baseline rating was overleaf and not readily visible, although the patient was not prevented from viewing it if they wished. At this time, the patient-centered efficacy question was asked by either the student assistant or the attending clinician (nurse or physician), and information on the specified adverse events was completed.

Student assistants confirmed the RASS rating with the attending physician. Other undefined adverse events of any type could be added by either the student or an attending clinician at any time during the ED episode of care. Regardless of other recorded responses, the patient was offered further antiemetic medication. Ondansetron 8 mg IV was recommended, but final choice was at physician discretion. When the inclusion criterion was met but the patient was not recruited, student assistants and recruiting ED clinicians were asked to record reasons for this (e.g. exclusion criteria, patient declined) on an enrollment form.

### **Data analysis**

Participant flow is reported using the Consort methodology; the analysis is intention to treat.

Baseline information of age, gender, initial severity and underlying condition are reported for each study site. Patients who were improved and those experiencing the desired effect are reported as number (%), and compared using the chi square test. As distribution approximates normal, VAS rating change is reported as mean mm with 95% confidence intervals (CI); mean VAS change was

compared using an independent samples t test. Use of additional medication and occurrence of adverse events are described.

Data were entered by one investigator (RM) into a secure database (Microsoft Excel 2007, Microsoft Corporation, Mountain View, CA USA) at which time it was de-identified. A random sample of 10% was checked for accuracy by another investigator (SC). Data were analyzed using Stata Version 12.0 statistical software (Stata Corporation, College Station, Texas, USA).

### **Sample Size**

This was informed by re-analysis of the raw data from one previous ED-based study, which compared ondansetron (4 mg IV) with placebo.<sup>6</sup> VAS reduction of  $\geq -8$  mm was reported by 79% and 57% of patients respectively.<sup>10</sup> Replication of this result required a sample of 111 per group to demonstrate superiority for ondansetron over placebo (alpha 0.05, beta 0.90). This would give a potential between-group difference of 22% (95% CI: 10 – 34) and number needed to treat (NNT) of 5 (95% CI: 3 – 10). While dependent on the clinical circumstances, a single digit NNT with an upper 95% confidence limit of ten or less would generally be considered clinically worthwhile.<sup>21</sup> For this reason, this level of difference was accepted as being clinically significant for this study. No corresponding information was available for droperidol. To allow for a drop-out rate of up to 10%, the aim was to recruit 126 patients per group, for a total of 378. The secondary outcomes were not considered relevant for sample size calculation.

## **Interim analysis and sensitivity analysis**

Due to ongoing concerns about the limited support for the calculated sample size, an interim analysis was performed after recruitment of 215 patients. Specialist statistical advice confirmed that there was no realistic prospect of demonstrating superiority for the active drugs over placebo by continuing recruitment to the planned sample size. A sensitivity analysis was conducted: additional potential treatment successes ('best imaginable' for the active drugs and 'lowest imaginable' for placebo) were calculated as follows: (remaining number per group to reach  $n = 111$ )  $\times$  (upper 95% confidence limit for active drugs or lower 95% confidence limit for placebo). This number was added to the actual number of improved patients in each group at the time of the analysis. 'Best imaginable' between-group differences were calculated from these theoretical treatment success rates.

## **Results**

### **Characteristics of the study subjects**

A total of 215 patients were recruited, 145 (68%) at Dandenong Hospital, 50 (23%) at Monash Medical Centre and 20 (9%) at Casey Hospital. The median age of all participants was 44 years (range 18 – 91), 40% were male and the mean baseline VAS rating was 61 mm (95% CI: 58 – 65).

There were no significant differences in baseline characteristics between sites. (Table 1) Patient flow is detailed in Figure 1.

Of the 215 patients, 73 (34%), 71 (33%) and 71 (33%) received droperidol, ondansetron and placebo, respectively. Similar proportions were recruited to each group at each study site; between-group differences for age, sex, baseline severity and diagnostic groupings were not significant. (Table 1)

The median time between study drug administration and the second VAS rating was 30 minutes (IQR: 30 – 35).

## **Main results**

### **Primary outcome**

Numbers with VAS change  $\geq$  -8 mm for droperidol, ondansetron and placebo were similar, being 55/73 (75%, 95% CI: 64 - 85), 57/71 (80%, 95% CI: 69 - 89) and 54/71 (76%, 95% CI: 64 - 85), respectively ( $p = 0.75$ , Pearson chi square). The between-group differences and NNT are shown in Table 2.

### **Secondary VAS-related outcomes**

The mean measured VAS changes for the droperidol, ondansetron and placebo groups were -29 mm (95% CI: -36 to -23), -34 mm (95% CI: -41 to -28) and -24 mm (95% CI: -29 to -19); the mean percentage VAS changes were -50% (95% CI: -59 to -40), -55% (95% CI: -64 to -46) and -41% (95% CI: -49 to -33) respectively. Percentage VAS change  $\geq$  -20% was reported by 74% (95% CI: 62 to 84), 75% (95% CI: 63 to 84) and 73% (95% CI: 61 to 83), respectively. Treatment having the desired effect was reported for droperidol, ondansetron and placebo by 77% (95% CI: 65 – 86), 73% (95% CI: 61 – 83) and 59%(95% CI: 47 – 71), respectively. Full values, between-group differences and NNT (where applicable) are shown in Table 2. Measured and percentage VAS reductions were significantly greater when the desired effect was experienced versus not (both  $p < 0.001$ , independent samples t test). For measured VAS change this was -39 mm (95% CI: -43 to -36) versus -7 mm (95% CI: -11 to -2); for percentage VAS change this was -66% (95% CI: -70 to -62) versus -8% (95% CI: -15 to -1).

Individual patient percentage VAS changes for those experiencing the desired treatment effect versus not are illustrated for each treatment group in Figure 2.

#### **Other secondary outcomes:**

Additional antiemetic medication was requested by 11/73 (15%, 95% CI: 8 – 25), 16/71 (23%, 95% CI: 13 – 34) and 21/71 (30%, 95% CI: 19 – 42), respectively. Of the 48 who requested extra medication, 43 (90%) had not experienced the desired treatment effect.

A reduced level of alertness (moderate sedation, light sedation or drowsiness) was noted significantly more often in the droperidol group, compared with the ondansetron and placebo groups (27/73 [37%, 95% CI: 26 – 49] versus 9/71 [13%, 95% CI: 6 – 23] and 12/71 [17%, 95% CI: 9 – 28] respectively,  $p = 0.001$  [Pearson chi square]). Restlessness or agitation was noted for 4/73 (5%, 95% CI: 2 – 13), 2/71 (3%, 95% CI: 0 – 10) and 2/71 (3%, 95% CI: 0 – 10), respectively. Headache was reported by 12/73 (16%), 13/71 (18%) and 20/71 (28%), respectively. Dizziness was reported by 11/73 (15%), 5/71 (7%) and 11/71 (15%), respectively.

#### **Sensitivity analysis and quality control**

Calculations for the sensitivity analysis, as defined, found that the greatest imaginable treatment success rates for droperidol and ondansetron, and lowest imaginable for placebo, were 87/111 (79%, 95% CI: 71 – 87) and 93/111 (84%, 95% CI: 77 – 91) versus 80/111 (72%, 95% CI: 64 – 80), respectively. The differences between the three groups was not statistically significant ( $p = 0.12$ , Pearson chi square). VAS change was re-measured from 22 randomly selected case report forms. Of these, the measured VAS change differed by 0-1 mm for 19 (87%), and by 2-3 mm for three (13%).

## Non-enrolled patients

Data were collected on 159 non-enrolled patients who met inclusion criteria. Median age was 49 years (IQR: 32 – 67) and 124 (78%) were female. Of the 159, 106 (67%) had exclusion criteria. The most frequent were: 43 (41%) received an antiemetic drug prior to ED arrival, 21 (20%) had cognitive impairment and 16 (15%) were pregnant. Of the 53 without exclusion criteria, 39 (74%) declined participation; the remaining 14 were not recruited for a variety of reasons including ED activity at the time and lack of an available study drug syringe.

## Discussion

For a population of adult ED patients with nausea from any underlying cause, this study did not demonstrate superiority for either droperidol or ondansetron in comparison with placebo. VAS reductions of  $\geq -8$  mm were reported by 75%, 80% and 76% respectively. While the between-group comparison favoured ondansetron over placebo, the 4% difference was not statistically significant; the NNT of 25 is not clinically worthwhile. This is not to say that all treatments are equally effective. This was not designed as an equivalence trial, which would be unusual for a placebo-controlled study. It should also be noted that in this setting, placebo does not equate with 'no treatment'. Patients are still being actively managed for the primary condition to which their nausea relates. As expected, the symptom improvement rates predicted by the percentage VAS change cut-off level of -20% were almost identical to those detected by the measured VAS change cut-off.

Although the primary outcome measure of symptom improvement differs from that used in the previous research on the topic, the finding remains generally consistent.<sup>4-7</sup> Ever since the first ED-based, placebo-controlled antiemetic trial was published in 2006,<sup>4</sup> there has been a consistent lack of support for the effectiveness of antiemetic drugs in the ED setting.<sup>4-7</sup> In the past, a number of

This article is protected by copyright. All rights reserved.



reasons have been proposed in the literature as to why the multiple study findings might be erroneous.<sup>8,9</sup> The difficulty in accepting that antiemetic drugs may offer little for ED patients might stem from the decades of apparent support for their effectiveness in the post-operative and oncology settings. In those fields, studies have consistently demonstrated that the prophylactic administration of antiemetic drugs reduces the incidence of post-stimulus (anaesthetic or chemotherapy) nausea and vomiting.<sup>22-26</sup> Interestingly, however, when nausea does develop after delivery of chemotherapy or in post-operative patients, difference in its severity has not been demonstrated between treatment groups.<sup>25,27</sup> Perhaps antiemetic drugs are more effective for prevention than they are for cure.

A number of the secondary outcomes were of interest. While the percentages reporting symptom improvement were similar between all groups, experiencing of the desired treatment effect was not. This was reported by 77% and 73% for droperidol and ondansetron, but only by 59% of the placebo group. This may seem inconsistent with the symptom improvement results, but these outcomes reflect different amounts of symptom change. The VAS change cut-off levels identify patients whose symptoms are either 'a little less' or 'a lot less', while experiencing the desired effect requires symptoms to be 'a lot less'.<sup>3</sup> Given this, the difference in the desired effect findings is most likely explained by the relative difference in the mean VAS changes between groups. For measured change, these were -29 mm, -34 mm and -24 mm for the droperidol, ondansetron and placebo groups. It is conceivable that the somewhat lesser mean VAS change for the placebo group resulted from fewer patients having the greater VAS reductions which are reported when symptoms become 'a lot less'. This inference is supported by relatively more in the placebo group requesting additional medication (30%) in comparison with the droperidol and ondansetron groups (15% and 23%). It has previously been reported that most patients wanting additional antiemetic medication are those who have improved but not by the desired amount.<sup>3</sup> The NNT for experiencing the desired effect of

5 and 7 for droperidol and ondansetron, in comparison with placebo, may be clinically worthwhile but these point estimates are fairly imprecise. Despite this, it may still be useful to balance this information against other factors such as drug costs and side-effects when making individual treatment recommendations. For the drugs used in this study, the costs are low and the reasonably minor adverse effects did not require any treatment.

The purpose of primarily comparing symptom improvement rates between groups was to enable findings which directly related to the primary treatment objective to be presented in a format which is easy to clinically interpret.<sup>10</sup> It was hoped that this would aid understanding of relative treatment effectiveness in a way which might be beneficial for both treating doctors and patients. It is not useful, for example, to inform a patient that without antiemetic drug treatment their nausea severity is likely to improve by about -24 mm on the VAS, but that on average, ondansetron might reduce it by -34 mm. The following seems far more helpful: 'Whether or not you have an anti-nausea drug, there is a 75 to 80% chance that your nausea will ease as your underlying condition is treated. Ondansetron might give a little extra benefit to about one-in-seven of those who do improve. There are some people, however, whose nausea will not quickly settle no matter what we do. Ondansetron may have some side-effects, but these are usually fairly mild.'

With regard to future ED-based antiemetic research, it should be remembered that the studies to date have only examined the response to a single administration of one drug at 30 or 60-minutes post-treatment. The response to higher drug doses, repeated dosages over a longer time period, or the concurrent delivery of antiemetic drugs from different groups may be quite different.

Characterizing treatment responders versus non-responders could also be of value and the need for condition-specific research has never been entirely discounted.<sup>28</sup>

## Limitations

Consideration of the outcome measures used in ED-based antiemetic studies remains important.

Between-group comparisons of mean VAS change have previously failed to demonstrate superiority for antiemetic drugs over placebo. The VAS change cut-off level included as an outcome measure in this study may have aided clinical interpretation of the results, but it also failed to demonstrate superiority for the active drugs. For ED patients, antiemetic drugs may truly provide little additional benefit to that derived from treatment of their underlying condition. It may also be that outcome measures and methods of analysis capable of detecting a real difference are yet to be determined and successfully trialled.

The original sample size calculation for the study was based on 'anticipated' symptom improvement rates for ondansetron and placebo of 79% and 57%. As this was drawn from a post-hoc analysis of only one study,<sup>6,10</sup> doubts about the accuracy of the estimate persisted. For this reason, conduct of an interim analysis was deemed prudent, and in retrospect, not pre-planning this was an error. At that time, it was found that the 'actual' and 'anticipated' symptom improvement rates for the placebo group were markedly different (76% versus 57%). Also, the mean VAS change of -29 mm for droperidol was much lower than the -55 mm previously reported.<sup>4</sup> The degree of these differences is probably not surprising given the known variation in mean VAS changes for the same treatment regimens in different ED-based studies. For example, two different studies reported post-treatment mean VAS changes for ondansetron (4 mg IV) of -34 mm and -22 mm,<sup>5,13</sup> two other studies reported mean VAS changes for placebo of -39 mm and -16 mm.<sup>4,5</sup> This is despite patient populations appearing otherwise similar.

Other potential limitations include that the convenience sample may not be representative of all ED patients with nausea. Recruitment was probably more frequent when student research assistants were present, but the number of patients enrolled by students versus duty clinical staff was not recorded. Although incomplete, monitoring of reasons for non-recruitment was attempted. Pre-hospital antiemetic administration was the most frequent reason for exclusion. This may have led to recruitment of fewer patients with severe nausea; the potential impact of this on results is unknown. Although the study instructions dictated that all patients have 1000 mL of IV 0.9% saline running at a four-hourly rate, exact amounts of fluid received during the 30-minute study period may have varied.

### **Conclusions**

For adult ED patients with nausea, this study did not demonstrate superior symptom improvement rates for droperidol 1.25 mg IV or ondansetron 8 mg IV in comparison with placebo. The marginally greater mean VAS reductions and rates of experiencing the desired treatment effect in the active drug groups may aid treatment decision making in individual cases.

### **Acknowledgements**

Specialist statistical advice regarding the interim and sensitivity analyses was obtained from Professor Rory Wolfe of the Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. This was invaluable. The assistance in recruitment from the following Monash University medical students is also acknowledged: Jeremy Lee, Sarah Monagle, Amos Liew, Helen Huang, Geoffrey Liu, Annabel Jones, Lucia Hadinata, Luke Fletcher, Tom de Vries, Liyin Yip, Stephanie See, Sean Ng Ying Kin, Novia Tan, Monique Kowitz, James Jiang and Sandy Chu.

## References

1. Mee MJ, Egerton-Warburton D, Meek R. Treatment and assessment of emergency department nausea and vomiting in Australasia: A survey of anti-emetic management. *Emerg Med Australas* 2011; **23**: 162–8.
2. Singer AJ, Garra G, Thode,HC. Do emergency department patients with nausea and vomiting desire, request, or receive antiemetics. *Am J Emerg Med* 2017; **35**: 790–1.
3. Meek R, Graudins A, Anthony S. Antiemetic treatment in the emergency department: Patient opinions and expectations. *Emerg Med Australas* 2018; **30**: 36–41.
4. Braude D, Soliz T, Crandall C, Hendey G, Andrews J, Weichenthal L. Antiemetics in the ED: a randomized controlled trial comparing 3 common agents. *Am J Emerg Med* 2006; **24**: 177–82.
5. Barrett TW, DiPersio DM, Jenkins CA *et al.* A randomized, placebo-controlled trial of ondansetron, metoclopramide, and promethazine in adults. *Am J Emerg Med* 2011; **29**: 247–55.
6. Egerton-Warburton D, Meek R, Mee MJ, Braitberg G. Antiemetic use for nausea and vomiting in adult emergency department patients: randomized controlled trial comparing ondansetron, metoclopramide, and placebo. *Ann Emerg Med* 2014; **64**: 526–32.
7. Furyk JS, Meek R, Egerton-Warburton D. Drugs for the treatment of nausea and vomiting in adults in the emergency department setting ( Review ). *Cochrane Database Syst Rev* **2015**: CD010106.
8. Singer AJ, Garra G, Thode HC. Oligoantiemesis or inadequate prescription of antiemetics in the ED: A local and national perspective. *J Emerg Med* ; **50**: 818–24.
9. Pitts SR. Neither ondansetron nor metoclopramide reduced nausea and vomiting in the

emergency department. *Ann Intern Med* 2014; **161**: JC3.

10. Meek R, Graudins A. Do antiemetic drugs benefit adult emergency department patients with nausea? The literature says no, but is it right? *Emerg Med Australas* 2017; **29**: 736–9.
11. Meek R, Egerton-Warburton D, Mee MJ, Braitberg G. Measurement and monitoring of nausea severity in emergency department patients: A comparison of scales and exploration of treatment efficacy outcome measures. *Acad Emerg Med* 2015; **22**: 685–93.
12. Ernst AA, Weiss SJ, Park S, Takakuwa KM, Diercks DB. Prochlorperazine versus promethazine for uncomplicated nausea and vomiting in the emergency department: a randomized, double-blind clinical trial. *Ann Emerg Med* 2000; **36**: 89–94.
13. Braude D, Crandall C. Ondansetron versus promethazine to treat acute undifferentiated nausea in the emergency department: a randomized, double-blind, noninferiority trial. *Acad Emerg Med* 2008; **15**: 209–15.
14. Chae J, Taylor DM, Frauman AG. Tropisetron versus metoclopramide for the treatment of nausea and vomiting in the emergency department: A randomized, double-blinded, clinical trial. *Emerg Med Australas* 2011; **23**: 554–61.
15. Patka J, Wu DT, Abraham P, Sobel RM. Randomized controlled trial of ondansetron vs prochlorperazine in adults in the Emergency Department. *West J Emerg Med* 2011; **26**: 217–20.
16. Hendey GW, Donner NF, Fuller K. Clinically significant changes in nausea as measured on a visual analog scale. *Ann Emerg Med* 2005; **45**: 77–81.
17. Meek R, Kelly A-M, Xue FH. Use of the visual analog scale to rate and monitor severity of nausea in the emergency department. *Acad Emerg Med* 2009; **16**: 1304–10.
18. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain. *Arthritis Care Res* 2011;

63: 240–52.

19. Meek, R. Graudins, A. Visual Analog Scale rating change cut-offs for detection of improvement in nausea severity. *Manuscr. Submitt. Publ.*
20. Altman, D. G. The cost of dichotomising continuous variables. *Bmj* **332**, 1080–1080 (2006).
21. Citrome, L. Quantifying clinical relevance. *Innov. Clin. Neurosci.* **11**, 26–30 (2014).
22. Carlisle J, Stevenson C. Drugs for preventing postoperative nausea and vomiting. *Cochrane Database Syst Rev* 2006: CD004125.
23. Bosnjak SM, Neskovic-Konstantinovic ZB, Radulovic SS, Susnjar S, Mitrovic LB. High efficacy of a single oral dose of ondansetron 8 mg versus a metoclopramide regimen in the prevention of acute emesis induced by fluorouracil, doxorubicin and cyclophosphamide (FAC) chemotherapy for breast cancer. *J Chemother* 2000; **12**: 446–53.
24. Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin co. *J Clin Oncol* 2012; **30**: 3998–4003.
25. Lindley C, Goodin S, McCune J *et al.* Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy. *Am J Clin Oncol* 2005; **28**: 270–6.
26. Takemoto H, Nishimura J, Komori T *et al.* Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea. *Int J Clin Oncol* 2016; **22**: 1–8.
27. Song Y, Shim J-K, Song J-W, Kim E-K, Kwak Y-L. Dexmedetomidine added to an opioid-based


analgesic regimen for the prevention of postoperative nausea and vomiting in highly susceptible patients. *Eur J Anaesthesiol* 2016; **33**: 75–83.

28. Sanger GJ, Andrews PLR. Treatment of nausea and vomiting: Gaps in our knowledge. *Auton Neurosci Basic Clin* 2006; **129**: 3–16.



**Figure 1. Patient flow diagram.**

DH = Dandenong Hospital, MMC = Monash Medical Centre, CH = Casey Hospital



**Table 1. Baseline variables: total population and comparison between treatment groups.**

Variable		Total (n = 215)	Droperidol (n = 73)	Ondansetron (n = 71)	Placebo (n = 71)
Study site	DH	145 (68%)	49 (67%) [55 – 78]	49 (69%) [57 – 79]	47 (66%) [54 – 77]
	MMC	50 (23%)	18 (25%) [15 – 36]	15 (25%) [12 – 32]	17 (24%) [15 – 36]
	CH	20 (9%)	6 (8%) [3 – 17]	7 (10%) [4 – 19]	7 (10%) [4 – 19]
Age: median years (IQR)		44 (32 – 60)	42 (31 – 61)	47 (36 – 63)	44 (26 – 58)
Male sex: n (%) [95% CI]		87 (40%) [34 – 47]	30 (41%) [30 – 53]	26 (37%) [25 – 49]	31 (44%) [32 – 56]
Baseline VAS: Median mm (IQR)		60 mm (47 – 75)	60 mm (47 – 80)	59 mm (47 – 75)	62 mm (46 – 75)
Major diagnostic groups (n > 10)	Gastro-enteritis	42 (20%)	11 (15%) [8 - 25]	12 (17%) [9 - 28]	19 (27%) [17 - 39]
	Infective illness	40 (19%)	17 (23%) [14 – 35]	9 (13%) [6 – 23]	14 (20%) [11 – 31]
	AP – U	29 (13%)	7 (10%) [4 – 19]	12 (17%) [9 – 28]	10 (14%) [7 – 24]
	AP – S	28 (13%)	10 (14%) [7 – 24]	10 (14%) [7 – 24]	8 (11%) [5 – 21]
	Opioid-related	17 (8%)	3 (4%) [1 – 12]	11 (15%) [8 – 26]	3 (4%) [1 – 12]
	Gastritis (type unspecified)	13 (6%)	9 (12%) [6 – 22]	0 (0%) [0 – 5]	4 (6%) [2 – 14]
	Drug/Alcohol (excluding pioids)	12 (6%)	4 (5%) [2 – 13]	4 (6%) [2 – 14]	4 (6%) [2 – 14]
	Other	34 (16%)	12 (16%) [9 – 27]	13 (18%) [10 – 29]	9 (13%) [6 – 23]

DH = Dandenong Hospital, MMC = Monash Medical Centre, CH = Casey Hospital

IQR = interquartile range; CI = confidence interval

AP – U = Abdominal pain, underlying condition unspecified/unknown

AP – S = Abdominal pain, associated with specified condition (e.g. appendicitis, pancreatitis)

**Table 2. VAS changes and experiencing of the desired effect: Individual treatment groups and between-group differences.**

Outcome measure	Individual treatment groups			Between-group differences		
	Droperidol (n = 73)	Ondansetron (n = 71)	Placebo (n = 71)	Droperidol – Placebo	Ondansetron – Placebo	Ondansetron - Droperidol
<b>Measured VAS change ≥ -8 mm: n (%) [95% CI]</b>	55 (75%) [64 to 85]	57 (80%) [69 to 89]	54 (76%) [64 to 85]	-1% [-15 to 13] NNT = 99*	4% [-10 to 18] NNT = 25	5% [-9 to 19] NNT = 20
<b>Mean measured VAS change: mm [95% CI]</b>	-29 mm [-36 to -23]	-34 mm [-41 to -28]	-24 mm [-29 to -19]	5 mm [-3 to 13]	10 mm [2 to 18]	5 mm [-4 to 14]
<b>Percentage VAS change ≥ 20%: n (%) [95% CI]</b>	54 (74%) [62 to 84]	53 (75%) [63 to 84]	52 (73%) [61 to 83]	1% [-13 to 15] NNT = 99	2% [-12 to 16] NNT = 50	-1% [-15 to 13] NNT = 99**
<b>Mean percentage VAS change: % [95% CI]</b>	-50% [-59 to -40]	-55% [-64 to -46]	-41% [-49 to -33]	9% [-3 to 21]	14% [-2 to 26]	5% [-8 to 18]
<b>Experienced desired effect: n (%) [95% CI]</b>	56 (77%) [65 to 86]	52 (73%) [61 to 83]	42 (59%) [47 to 71]	18% [3 to 33] NNT = 5	14% [-1 to 29] NNT = 7	-4% [-18 to 10] NNT = 5**

VAS = Visual Analog Scale; CI = Confidence Interval; NNT = Number Needed to Treat

\* Favoring placebo, \*\*Favoring droperidol; Others favor first named treatment.

**Figure 2. Individual percentage VAS changes: desired treatment effect or not for each treatment group.**

Note: Percentage VAS change is shown for each patient in sequence from the largest to the least amounts of reported change.

